Additional long-term data from the TRiMM-2 study in patients receiving talquetamab and DARZALEX FASPRO® combination biweekly regimen showed an overall response rate of more than 80 percent...

The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the first-ever results from the Phase 1b RedirecTT-1 study of TECVAYLI® (teclistamab-cqyv), a first-in-class BCMAxCD3...

– PRGN-2009 combined with an investigational checkpoint inhibitor resulted in a 30% ORR in patients with heavily pre-treated HPV-associated cancers that were naïve or resistant to checkpoint...

-- Breadth of pipeline featured in multiple early clinical data presentations, reflecting diversity of fundamental growth drivers across development programs -- CAMBRIDGE, Mass., June 3, 2023...

Initial data showed promising signs of efficacy, including a 47.1% ORR in patients with resistant/refractory gastric cancer expressing Claudin 18.2, with a well-tolerated safety profile Elevation...

Compared To Synthetic Controls, INT230-6 Alone Extended Survival In Refractory Soft Tissue Sarcoma Subjects by Nearly 450 Days With Favorable Safety INT230-6, a Locally Delivered Cytotoxic...

-- Patricia Mae Garcia Santos, MD, MS, receives annual Conquer Cancer-Women Leaders in Oncology "Women Who Conquer Cancer" Young Investigator Award -- -- Tafadzwa L. Chaunzwa, MD, MHS, receives...

The Howard Hughes Corporation® (NYSE: HHC) announced today that Chief Executive Officer David O'Reilly will participate in a presentation moderated by Anthony Paolone from JP Morgan at NAREIT's...

"Between Two Worlds" Awarded Grand Prize at Gala Event, 2023 Auggie Award Winners Also Announced SANTA CLARA, Calif., June 2, 2023 /PRNewswire/ -- Augmented World Expo (AWE), the leading series of...

Promontory Therapeutics Inc., a clinical stage pharmaceutical company advancing small molecule immunotherapies in oncology, announces preliminary data from a Phase 2 clinical trial of the...